Last reviewed · How we verify
SER-262
At a glance
| Generic name | SER-262 |
|---|---|
| Also known as | Cultivated Eubacterial Spore Suspension, Encapsulated |
| Sponsor | Seres Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SER-262 CI brief — competitive landscape report
- SER-262 updates RSS · CI watch RSS
- Seres Therapeutics, Inc. portfolio CI